ProCE Banner Activity

CAPELLA: Resistance Analysis in Highly Treatment–Experienced Patients Receiving LA Lenacapavir

Slideset Download
Conference Coverage
Through 26 weeks, viral rebound on lenacapavir plus optimized background was associated with a lack of additional active ARVs resulting in functional LEN monotherapy.

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp

ViiV Healthcare